Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)
Close on Nov 17, 2026Market cap $666.15MP/E –Yield –
Fulgent Genetics r&d expenses
Research and development expenses are spending on new products and technology.
Fulgent Genetics's R&D Expenses for the twelve months ending Jun 30, 2026 was $56.76M, up 14.0% year over year. For fiscal 2025 it was $53.91M, up 10.4% from the year before. Over ten years it grew 28.4% a year on average. The highest annual figure on record is $53.91M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.91M | +10.4% |
| FY2024 | Dec 31, 2024 | $48.82M | +17.8% |
| FY2023 | Dec 31, 2023 | $41.44M | +43.3% |
| FY2022 | Dec 31, 2022 | $28.91M | +19.4% |
| FY2021 | Dec 31, 2021 | $24.22M | +109.1% |
| FY2020 | Dec 31, 2020 | $11.58M | +77.1% |
| FY2019 | Dec 31, 2019 | $6.54M | +18.1% |
| FY2018 | Dec 31, 2018 | $5.53M | +31.0% |
| FY2017 | Dec 31, 2017 | $4.22M | +18.7% |
| FY2016 | Dec 31, 2016 | $3.56M | -19.7% |
| FY2015 | Dec 31, 2015 | $4.43M | +750.5% |
| FY2014 | Dec 31, 2014 | $521.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.55M | +8.0% |
| Q1 FY2026 | Mar 31, 2026 | $14.18M | +14.4% |
| Q4 FY2025 | Dec 31, 2025 | $14.17M | +17.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.86M | +17.6% |
| Q2 FY2025 | Jun 30, 2025 | $13.48M | -0.0% |
| Q1 FY2025 | Mar 31, 2025 | $12.40M | +8.4% |
| Q4 FY2024 | Dec 31, 2024 | $12.11M | +1.3% |
| Q3 FY2024 | Sep 30, 2024 | $11.78M | +17.7% |
| Q2 FY2024 | Jun 30, 2024 | $13.49M | +39.1% |
| Q1 FY2024 | Mar 31, 2024 | $11.43M | +16.9% |
| Q4 FY2023 | Dec 31, 2023 | $11.95M | +40.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.01M | +33.4% |
| Q2 FY2023 | Jun 30, 2023 | $9.69M | +40.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.78M | +63.3% |
| Q4 FY2022 | Dec 31, 2022 | $8.51M | +14.0% |
| Q3 FY2022 | Sep 30, 2022 | $7.51M | +24.7% |
| Q2 FY2022 | Jun 30, 2022 | $6.91M | +30.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.99M | +10.5% |
| Q4 FY2021 | Dec 31, 2021 | $7.46M | +63.1% |
| Q3 FY2021 | Sep 30, 2021 | $6.02M | +89.5% |
| Q2 FY2021 | Jun 30, 2021 | $5.31M | +187.3% |
| Q1 FY2021 | Mar 31, 2021 | $5.42M | +174.1% |
| Q4 FY2020 | Dec 31, 2020 | $4.58M | +154.9% |
| Q3 FY2020 | Sep 30, 2020 | $3.18M | +82.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.85M | +17.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.98M | +38.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.80M | +25.9% |
| Q3 FY2019 | Sep 30, 2019 | $1.74M | +21.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.57M | +29.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.42M | -2.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.43M | +7.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.44M | +27.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.21M | +31.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.46M | +71.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.32M | +61.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.13M | -25.9% |
| Q2 FY2017 | Jun 30, 2017 | $920.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $851.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $818.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $1.52M | – |
See a number that looks wrong?